Pharmacological advances for treatment in Duchenne muscular dystrophy
Open Access
- 1 June 2017
- journal article
- research article
- Published by Elsevier BV in Current Opinion in Pharmacology
- Vol. 34, 36-48
- https://doi.org/10.1016/j.coph.2017.04.002
Abstract
No abstract availableKeywords
Funding Information
- Medical Research Council
- Muscular Dystrophy UK
- Duchenne UK
- Summit Therapeutics plc
This publication has 61 references indexed in Scilit:
- VBP15, a novel anti‐inflammatory and membrane‐stabilizer, improves muscular dystrophy without side effectsEMBO Molecular Medicine, 2013
- Translational Regulation of Utrophin by miRNAsPLOS ONE, 2011
- Drug Discovery for Duchenne Muscular Dystrophy via Utrophin Promoter Activation ScreeningPLOS ONE, 2011
- Daily Treatment with SMTC1100, a Novel Small Molecule Utrophin Upregulator, Dramatically Reduces the Dystrophic Symptoms in the mdx MousePLOS ONE, 2011
- CINRG pilot trial of coenzyme Q10 in steroid‐treated duchenne muscular dystrophyMuscle & Nerve, 2011
- Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx miceProceedings of the National Academy of Sciences, 2010
- Debio-025 is more effective than prednisone in reducing muscular pathology in mdx miceNeuromuscular Disorders, 2010
- HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatmentProceedings of the National Academy of Sciences, 2008
- Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginoneNeuromuscular Disorders, 2008
- Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic ProteinsClinical Pharmacokinetics, 2005